Last reviewed · How we verify
NCT06233409: STMIK
A Novel Sandwich Technique of Minimally Invasive Keratoplasty for Corneal Perforation
trial in Corneal Perforation, Corneal Stromal Lenticule,Sandwich Technique in 30 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Tianjin Eye Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 23 October 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Conditions studied
- Corneal Perforation, Corneal Stromal Lenticule,Sandwich Technique — all drugs for Corneal Perforation, Corneal Stromal Lenticule,Sandwich Technique →
Sponsor
Tianjin Eye Hospital
Who can join
Eligibility, any sex, with Corneal Perforation, Corneal Stromal Lenticule,Sandwich Technique. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this type of study to describe a new sandwich technique of minimally invasive keratoplasty (STMIK) by using SMILE-extracted lenticules for treatment corneal perforation and effectiveness. The main question\[s\] it aims to answer are: 1.Corneal perforations require urgent attendances for prompt treatments. How can we restore the integrity of the eyeball as soon as possible, reduce complications, and restore vision in the case of lack of corneal material according to the conditions that may be obtained. 2.In China, nearly 1 million lenticules are obtained through all-femtosecond surgery every year. How to reuse and turn waste into precious materials for clinical application is an important study. Participants will understand and signed the informed consent to take this new method for the treatment of their corneal perforations disease, which will obtain good results, but there may be a certain risk of complications.The main tasks participants will be asked to cooperate as required.The clinical eye check includes the test of includes visual acuity, slit lamp, anterior segment phase, anterior segment OCT and IOP.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A novel sandwich technique of minimally invasive surgery for corneal perforation.
Chen L, Dong Y, Jiang L, Xiao B, et al · · 2024 · PMID 39533004 · DOI 10.1038/s41598-024-79376-1
Verify or expand the search:
- PubMed search for NCT06233409
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Tianjin Eye Hospital trials
Trials by the same sponsor.
- NCT07518316 — Factors Influencing Subjective Visual Quality in Human Eyes · NA · not yet recruiting
- NCT06993077 — Impact of Ultraviolet Radiation and Environmental Factors on Human Ocular Biomechanics · active not recruiting
- NCT06694051 — Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism · NA · recruiting
- NCT07244276 — Comparison of Compressed Continuous Suture and Conventional Suture in Pterygium Surgery · NA · recruiting
- NCT07171710 — Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögr · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06233409 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Eye Hospital
- Last refreshed: 31 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06233409.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing